comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-06 08:39:13 - browse：3

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： First medicine developed to treat MASH expected to be approved soon

knowledge

WSS

Readout LOUD podcast: possible new ALS drug, artificial wombs

RSV shot was 90% effective at preventing hospitalizations in kids

Amylyx ALS drug failure raises questions and concerns

What Congress can do to address the rural doctor shortage

Headspace, Meta partner to launch VR meditation app for Quest

The problem with charging patients to message their doctors

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sen. Paul opposes bill to ban Chinese biotechs

Duchenne breakthrough therapy leaves behind pioneering families

IVF, abortion rights issues kick off Biden’s State of the Union

Virginia high school admissions case could be legal follow

Emergency workers more likely to restrain Black patients: study

BioMarin wins approval for gene therapy to treat hemophilia A

Intarcia’s device

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What it’s like to watch children die of measles

explore

Amylyx ALS drug failure raises questions and concerns

STAT Virtual Event: Putting AI to the Test

Senate HELP committee spars over health care workforce policies

Hearing on Medicare drug price negotiation gets unusually heated

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

EpiPen alternative approval delay highlights citizen petition issue

knowledge

entertainment

hotspot

focus